NASDAQ:CLDX Celldex Therapeutics Q3 2026 Earnings Results & Report $28.27 -1.66 (-5.55%) Closing price 11/5/2026 04:00 PM EasternExtended Trading$27.95 -0.32 (-1.13%) As of 04:12 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Celldex Therapeutics beat analyst earnings expectations but missed on revenue in its Q3 2026 results, released November 5, 2026. The company reported EPS of -$0.96 versus the -$1.02 consensus estimate, while revenue of $400 thousand fell short of the $723 thousand estimate by $323.00 thousand. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 5, 2026TimeAfter Market ClosesConference Call4:00 PM ET Celldex Therapeutics EPS ResultsActual EPS-$0.96Consensus EPS -$1.02Beat/MissBeat by +$0.06One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersCelldex Therapeutics Revenue ResultsActual Revenue$400 thousandExpected Revenue$723 thousandBeat/MissMissed by -$323.00 thousandYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Celldex Therapeutics Q3 2026 Earnings FAQ Did Celldex Therapeutics beat earnings estimates for Q3 2026? Celldex Therapeutics (NASDAQ:CLDX) reported earnings of -$0.96 per share for Q3 2026, beating the consensus estimate of -$1.02. The report was announced on Thursday, November 5, 2026. What was Celldex Therapeutics' revenue for Q3 2026? Celldex Therapeutics reported revenue of $400 thousand for Q3 2026, against a consensus estimate of $723 thousand. Celldex Therapeutics Earnings HeadlinesCelldex Therapeutics, Inc. (NASDAQ:CLDX) Stock Has Consensus Target Price of $63.08November 3 at 2:15 AM | americanbankingnews.comCelldex Therapeutics (CLDX) Stock Looks Rich After Shareholder InvestigationOctober 17, 2026 | finance.yahoo.comMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks. | Weiss Ratings (Ad)SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX)October 12, 2026 | prnewswire.comCelldex Therapeutics: Trying To Put Its Troubled History Behind ItOctober 7, 2026 | seekingalpha.comCelldex (CLDX) Receives a Rating Update from a Top AnalystOctober 4, 2026 | theglobeandmail.comSee More Celldex Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Celldex Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Celldex Therapeutics and other key companies, straight to your email. Email Address About Celldex TherapeuticsCelldex Therapeutics (NASDAQ:CLDX) is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing targeted therapeutics for diseases with significant unmet medical needs. The company uses antibody-based technologies to develop treatments intended to modulate the immune system and address inflammatory, autoimmune and other serious conditions. Celldex’s lead investigational product is barzolvolimab, an antibody designed to selectively block the KIT receptor and reduce mast-cell activity. The therapy is being evaluated in clinical studies for conditions including chronic spontaneous urticaria and prurigo nodularis. Celldex also maintains a broader pipeline of antibody-based programs targeting immune and inflammatory pathways. Its products remain investigational and require regulatory approval before they can be marketed. Based in Hampton, New Jersey, Celldex conducts research and clinical development activities in the United States and works with research and clinical partners in other regions as its programs advance. The company is led by President and Chief Executive Officer Anthony S. Marucci.View Celldex Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to WatchQualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a CatchUber's Profit Drop: A Speed Bump or Structural Shift?Boeing Has the Orders, the Cash Flow, and Insider Buyers, But What's Still Missing?Keurig Dr Pepper's Beverage Growth Raises a Tough Question About Its Coffee SplitAmazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?Datadog's Post-Earnings Sell-Off: A Buying Opportunity in Plain Sight? Upcoming Earnings Occidental Petroleum (11/9/2026)KKR & Co. Inc. (11/9/2026)Barrick Mining (11/9/2026)Constellation Energy (11/9/2026)Petroleo Brasileiro S.A.- Petrobras (11/10/2026)Transdigm Group (11/10/2026)Honda Motor (11/11/2026)Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
